ISA Pharmaceuticals strengthens its Supervisory Board with the appointment of Professor Jan van de Winkel

FDA grants ISA Pharmaceuticals Orphan Drug Designation for the treatment of Vulvar Intraepithelial Neoplasia with its lead product ISA-HPV-SLP®

ISA Pharmaceuticals closes a License Agreement with Transgene aimed at the development of novel vaccines for TB